Can patient-generated data from surveys and wearable sensors predict survival and other key oncological outcomes?

wePRO BASE is a prospective real-world cohort study investigating whether baseline data from consumer-grade wearable sensors and from electronic patient-reported outcome (ePRO) surveys can complement clinician-rated performance status in terms of predicting relevant oncological outcomes such as hospitalisation, toxicity and survival. BASE stands for Baseline Ability Status Evaluation.

This ethics-approved study was conducted at the Radiation Oncology department of the Northern Sydney Cancer Centre (NSCC) located at Royal North Shore Hospital (RNSH) in Sydney. Using a pragmatic recruitment approach we aimed to offer a wearable sensor to every patient receiving radiotherapy.

Between June 2022 and January 2024 we enrolled n = 751 patients, which constitutes the largest, non-pooled wearable device study in oncology based on a recent systemic review by Chow et al. We are currently analysing the data for the first clinical paper, which we anticipate to be published in 2025.

Huge thanks to all participating patients, to the facilitating NSCC staff and the following two funding sources:

BASE consent and wearable device loan process

Thilo Schuler MD MHInf
Thilo Schuler MD MHInf
Radiation Oncology Doctor

I am a practicing medical doctor with 10 years’ experience in Radiation Oncology and long track record of successful implementation of digital health projects to drive innovation in clinical research and practice. My passion to improve cancer care with digital health has led me to pursue a PhD. It focuses on the translation of patient-generated health data in routine oncology care to optimally support cancer patients and their families.

Related